

type of report	Current report
number	33/2013
company	PHARMENA

Introduction of pre-emptive rights, allotment certificates, series D shares of Pharmena S.A. to trading on the NewConnect market

The Management Board of PHARMENA S.A. informs that the Management Board of Warsaw Stock Exchange decided, in its resolution no. 603/2013 of 3rd June 2013, to introduce to alternative trading system on the NewConnect market:

1) 7,036,042 (seven million thirty-six thousand and forty-two) pre-emptive rights to series D ordinary bearer shares of PHARMENA S.A. of a nominal value of 0.10 PLN each;

2) up to 1,759,010 (up to one million seven hundred fifty-nine thousand and ten) allotment certificates for series D ordinary bearer shares of PHARMENA S.A. of a nominal value of 0.10 PLN each, under the condition that such an issue of shares and their allotment is effected;

3) up to 1,759,010 (up to one million seven hundred fifty-nine thousand and ten) series D ordinary bearer shares of PHARMENA S.A. of a nominal value of 0.10 PLN, under the condition that the increase of PHARMENA S.A. company's share capital carried out through the issue of new shares is registered.

The funds obtained from the issue of series D shares will be assigned to clinical trials, carried out by Cortria Company, on phase II trials ("Proof of Concept") of innovative anti-atherosclerosis medicinal product 1-MNA to confirm the efficacy of 1-MNA active substance with increased doses.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wiczorkowska – Vice President of the Board